EZH2 Inhibitors: How They Work and Their Use in Cancer

EZH2 inhibitors are a class of targeted cancer drugs that work by blocking a specific enzyme, EZH2, which silences genes. When EZH2 is overactive or mutated, it can shut down tumor suppressor genes that would otherwise keep cell growth in check, effectively giving cancer cells a green light to multiply. The first EZH2 inhibitor, tazemetostat, earned FDA approval in 2020 for two types of cancer, and the field has expanded rapidly since then, with combination strategies and next-generation compounds in development.

What EZH2 Does in Healthy Cells

EZH2 is the catalytic engine of a larger protein assembly called Polycomb Repressive Complex 2 (PRC2). Its main job is to add chemical tags, specifically methyl groups, to a particular spot on histone proteins that DNA wraps around. This tagging, known as H3K27 trimethylation, acts like a “do not read” sign on nearby genes, keeping them silent.¹ Gene silencing sounds ominous, but it is a routine part of development. Cells need to turn off certain genes at the right times to become specialized: a liver cell does not need the same genetic programs running as a skin cell. EZH2 is particularly active in germinal center B cells, the immune cells that undergo rapid division inside lymph nodes when you fight an infection, where it temporarily silences cell-cycle checkpoints and differentiation genes to allow a burst of proliferation.²

This normal function becomes a problem when it does not switch off. If EZH2 stays highly active or acquires mutations that ramp up its tagging ability, genes that are supposed to restrain growth remain permanently silent.

How EZH2 Goes Wrong in Cancer

EZH2 is implicated in cancer through two distinct routes. In some cancers, gain-of-function mutations make the enzyme hyperactive, stamping too many silencing marks on chromatin. In other cancers, the enzyme itself is not mutated but is simply produced in excess. Both scenarios lead to the same downstream result: tumor suppressor genes get silenced, and programs that drive cell survival, proliferation, invasion, and drug resistance get the upper hand.³ What makes the picture more complex is that loss-of-function mutations in EZH2 also appear in certain cancers, though these are associated with entirely different tumor types.⁴ This means EZH2 is not uniformly “bad” across all cancers; its role depends on the specific disease context, which has real implications for who should and should not receive an EZH2 inhibitor.

Beyond its classic gene-silencing function, EZH2 has a secondary life that researchers are still working out. In advanced prostate cancer, for instance, EZH2 can actually switch roles and activate gene transcription, turning on the androgen receptor gene by directly sitting on its promoter. This activating function is independent of PRC2 and does not require EZH2’s methylation activity at all.⁵ The dual nature of EZH2 as both a silencer and, in certain contexts, an activator complicates the therapeutic picture and is one reason researchers have been exploring drugs that destroy the entire EZH2 protein rather than just blocking its enzymatic activity.

How EZH2 Inhibitors Block the Enzyme

Most EZH2 inhibitors in clinical use or in trials work by fitting into the enzyme’s active site, the pocket where EZH2 would normally bind its methyl-donor molecule and transfer methyl groups onto histones. By occupying that pocket, the drug prevents H3K27 trimethylation from happening.⁶ Without the silencing marks, tumor suppressor genes that had been shut off gradually reactivate. The cell starts receiving “stop growing” signals it had been ignoring.

This mechanism means EZH2 inhibitors do not kill cancer cells directly the way traditional chemotherapy does. Instead, they reprogram the cell’s gene expression over days to weeks, restoring normal regulatory circuits. Responses tend to be slower compared with cytotoxic drugs, but the tradeoff is a generally milder side-effect profile because the drugs are not damaging DNA or disrupting cell division across the board.

Tazemetostat and Its Approved Uses

Tazemetostat (brand name Tazverik) became the first FDA-approved EZH2 inhibitor in January 2020 for adults with epithelioid sarcoma, a rare soft-tissue cancer that is not eligible for complete surgical removal. Epithelioid sarcomas frequently lose a protein called INI1 (also known as SMARCB1), which is part of a chromatin remodeling complex that normally counterbalances EZH2. Without INI1, EZH2 activity goes essentially unopposed, making these tumors particularly vulnerable to EZH2 inhibition. In a phase 2 basket study, tazemetostat showed clinical activity and was well tolerated in patients with advanced epithelioid sarcoma characterized by INI1 loss.⁷ A more recent Japanese trial confirmed these findings, reporting a median overall survival of about 12 months and manageable side effects, with no treatment-related deaths.⁸

Later in 2020, tazemetostat received a second FDA approval for relapsed or refractory follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, in adults who had already tried at least two prior therapies. Here the drug’s benefit was clearest in patients whose tumors carried a specific EZH2 mutation: about 69% of those patients responded to treatment, compared with about 35% of patients whose tumors had normal (wild-type) EZH2.⁹ Complete responses, meaning no detectable disease, occurred in about 13% of the mutated group versus 4% in the wild-type group. Median progression-free survival was roughly 14 months in the mutated cohort and 11 months in the wild-type cohort.¹⁰ The fact that even wild-type patients showed meaningful responses suggests EZH2 overexpression alone, without a specific mutation, can make tumors at least partly dependent on the enzyme.

Side Effects and Safety Profile

Compared with conventional chemotherapy, EZH2 inhibitors are generally easier on patients. A systematic review and meta-analysis pooling data from hundreds of patients across multiple trials found that the most frequently reported side effects were drops in blood cell counts and mild gastrointestinal complaints. In terms of lab abnormalities, roughly 30% of patients experienced low platelet counts, about a quarter had anemia, and around 22% had low neutrophil counts. Among symptoms patients could feel, about a quarter reported nausea, a similar proportion had fatigue, and roughly one in five noticed decreased appetite or hair thinning.¹¹ Severe side effects (grade 3 or higher) were much less common: serious neutropenia and serious thrombocytopenia each occurred in about 8% of patients, and serious anemia in about 6%.¹¹

Real-world data from the FDA’s adverse event reporting system largely echoed these patterns, with fatigue, nausea, decreased appetite, and anemia among the most commonly filed reports for tazemetostat.¹² The overall picture is of a drug class that most patients can tolerate on an outpatient basis, though blood counts need regular monitoring. One area that warrants continued attention is the potential for secondary malignancies: because EZH2 normally helps regulate immune cell development, long-term suppression of its activity could theoretically affect immune surveillance, a risk that longer follow-up data will clarify.

Why Tumors Stop Responding

Like most targeted therapies, EZH2 inhibitors face the problem of resistance. Research on diffuse large B-cell lymphoma (DLBCL) cells has revealed at least two major escape routes. First, cancer cells can activate alternative growth-signaling pathways, including IGF-1R, MEK, and PI3K, essentially finding detours around the roadblock the drug creates. Second, the EZH2 gene itself can acquire new mutations that physically prevent the inhibitor from binding to the enzyme’s active site.¹³ Either mechanism alone is enough to restore cancer growth in the presence of the drug.

In tumors where the SWI/SNF chromatin-remodeling complex is disrupted (as in ARID1A-mutated cancers), resistance can also emerge through changes in the composition of the SWI/SNF complex itself. Switching between different catalytic subunits within SWI/SNF can blunt the synthetic lethality that made these tumors sensitive to EZH2 inhibition in the first place.¹⁴ These findings underscore why combination approaches and next-generation drugs are getting so much attention.

Synthetic Lethality and ARID1A-Mutated Cancers

One of the most exciting angles in EZH2 inhibitor research involves a concept called synthetic lethality, where two genetic events are each survivable on their own but lethal in combination. Cancers that have lost the tumor suppressor ARID1A, a common event in ovarian clear cell carcinoma and several other tumor types, become heavily dependent on EZH2 for survival. Blocking EZH2 in these cells exploits that dependency and triggers cell death, even though the same drug might have only a modest effect in ARID1A-intact tumors.¹⁵ This approach is appealing because it provides a clear biomarker for patient selection: if a tumor is ARID1A-mutated, it may be a strong candidate for EZH2 inhibitor therapy regardless of EZH2’s own mutational status.

EZH2 and the Tumor Microenvironment

EZH2’s influence extends beyond the tumor cells themselves. In the blood vessels that feed tumors, EZH2 promotes angiogenesis, the formation of new blood vessels that supply a growing tumor with oxygen and nutrients. Research in ovarian cancer found that EZH2 in tumor-associated blood vessel cells silences a natural angiogenesis inhibitor called vasohibin1. Knocking down EZH2 in those endothelial cells reactivated vasohibin1, slowed new vessel formation, and reduced tumor growth. The effect was even stronger when EZH2 was suppressed in both the blood vessel cells and the tumor cells simultaneously.¹⁶ Similar anti-angiogenic effects have been observed in nasopharyngeal carcinoma, where EZH2 knockdown suppressed tumor growth, metastasis, and blood vessel formation.¹⁷ Pharmacological EZH2 inhibition with GSK126 has also been shown to reduce levels of VEGF-A, a key pro-angiogenic signal, in a dose-dependent manner.¹⁸

EZH2 also shapes the immune landscape around tumors. In at least some models, EZH2 activity in cancer cells suppresses the production of chemical signals that recruit immune cells into the tumor. Blocking EZH2 can restore those signals and increase the presence of immune cells capable of attacking the cancer, which sets the stage for powerful combinations with immunotherapy.

Combining EZH2 Inhibitors with Immunotherapy

Some of the strongest preclinical momentum right now is around pairing EZH2 inhibitors with immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies. The logic is straightforward: if EZH2 inhibition reactivates immune-attracting signals in tumors, adding a checkpoint inhibitor at the same time should amplify the immune attack. In a mouse model of ovarian cancer, EZH2 inhibition boosted key T-cell-attracting chemokines (CXCL9 and CXCL10), increased the infiltration of effector T cells, and enhanced the effects of anti-PD-L1 treatment. In melanoma, anti-CTLA-4 therapy itself was found to upregulate EZH2 in tumor cells, reducing immunogenicity, and adding an EZH2 inhibitor countered that escape mechanism and substantially slowed tumor growth.¹⁹ A newer study confirmed this approach in lung adenocarcinoma, showing that a novel EZH2 inhibitor enhanced anti-tumor immunity and worked synergistically with PD-1 blockade.²⁰

For prostate cancer, the combination story takes a different angle. Castration-resistant prostate cancer (CRPC) often stops responding to hormonal therapies like enzalutamide. Preclinical work has shown that adding an EZH2 inhibitor can restore sensitivity to enzalutamide in CRPC cell lines that had become resistant to hormonal therapy alone.²¹ The combination also produced synergistic anti-cancer effects, including increased cell death and reduced activity of key survival signals, providing a preclinical rationale for dual targeting of the androgen receptor and EZH2 pathways.²²

Pediatric Cancers and Rhabdoid Tumors

EZH2 inhibitors hold particular promise for pediatric brain tumors with few existing treatment options. Malignant rhabdoid tumors and atypical teratoid/rhabdoid tumors (AT/RT) are aggressive childhood cancers that frequently lose the same SMARCB1/INI1 protein implicated in epithelioid sarcoma, creating a similar dependency on EZH2. In preclinical models, EZH2 inhibition significantly slowed rhabdoid tumor growth and prolonged the time before tumors progressed, though it typically did not cause tumors to shrink completely on its own.²³ Combining EZH2 inhibition with a BRD4 inhibitor improved the benefit beyond either drug alone in AT/RT models.²⁴

An interesting twist comes from research on pediatric diffuse midline gliomas (which include the historically devastating DIPG), where EZH2 inhibitors showed anti-tumor effects in animal models but not when applied directly to tumor cells in a dish. Researchers proposed that the benefit may come partly from targeting EZH2 in tumor-associated immune cells called microglia rather than in the cancer cells themselves.²⁵ This finding reinforces the idea that the tumor microenvironment is as important as the tumor cells when it comes to EZH2 biology.

Biomarkers for Patient Selection

Figuring out which patients are most likely to benefit from EZH2 inhibitors remains an active area of work. The clearest biomarker so far is the presence of a gain-of-function EZH2 mutation, as seen in follicular lymphoma, where response rates roughly double in mutated versus wild-type tumors. Loss of INI1/SMARCB1, as in epithelioid sarcoma and rhabdoid tumors, is another strong selection criterion because it signals a tumor microenvironment where EZH2 operates virtually unchecked.

EZH2 overexpression itself, without any mutation, has been proposed as a prognostic marker in several solid tumors. In esophageal squamous cell carcinoma, for example, high EZH2 and H3K27me3 levels in tumor tissue correlated with worse survival and more metastasis compared to surrounding normal tissue.²⁶ Whether high expression alone reliably predicts who will respond to EZH2 inhibitors, as opposed to simply marking aggressive disease, is still being sorted out in clinical trials. ARID1A mutation status is another candidate biomarker, given the synthetic lethality data, though prospective clinical validation is ongoing.

Next-Generation Approaches

The field is not standing still with first-generation catalytic inhibitors. Several next-generation strategies are in development to tackle the limitations of current drugs, particularly resistance and the non-catalytic roles of EZH2 that a simple enzyme-blocker cannot address. These include dual EZH1/EZH2 inhibitors, which block both closely related enzymes to prevent the compensatory activity that can occur when only EZH2 is suppressed. PROTAC-based degraders represent a fundamentally different approach: instead of just inhibiting EZH2’s enzymatic function, they hijack the cell’s own protein-disposal machinery to destroy the entire EZH2 protein. This could neutralize both the catalytic and non-catalytic roles of EZH2 in a single stroke.²⁷

Combination regimens with immunotherapy or hormonal therapy are also being actively explored in clinical trials, building on the preclinical rationale described earlier. The hope is that these strategies will extend the reach of EZH2-targeted therapy beyond the two current approved indications and into broader cancer populations.

EZH2 Inhibitors Beyond Cancer

Because EZH2 silences genes through the same histone-tagging mechanism in all cell types, researchers have explored whether EZH2 inhibitors could be useful outside oncology. One area of interest is HIV cure research. The virus can hide in a dormant state within immune cells, protected from both the immune system and antiretroviral drugs. Agents that reverse this latency, called latency-reversing agents, are needed to flush the virus out of hiding. EZH2 inhibitors have been shown to reactivate dormant HIV by removing the silencing marks that keep the viral DNA quiet, suggesting PRC2 components could be targets for latency reversal strategies.²⁸ This work is still early-stage, but it illustrates how a drug developed for cancer can find entirely unexpected applications when you understand its underlying mechanism.